AACR Report: AI Screening Tools Could Boost Cancer Detection and Cut Radiologist Workload

AI-assisted mammography showed 12% fewer interval cancers (MASAI trial) and greater sensitivity without specificity loss. Two cleared AI lung tools reduced false positives by 18% (RevealAI-Lung) and achieved 93% sensitivity (eyonis LCS). AI could decrease reading workload by 44%.

• Overall five-year survival for distant-stage cancer doubled from 17% to 36% over three decades, but pancreatic cancer survival remains 14%.
• AI-supported mammography detected early breast cancer with greater sensitivity without sacrificing specificity; the MASAI trial reported a 12% lower interval cancer rate.
• FDA-cleared AI tools for lung screening: RevealAI-Lung cut false positives by 18%, eyonis LCS showed 93% sensitivity; AI may reduce radiologist reading workload by 44%.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.